“The patient experience program is everything that has to do with the drug and what you surround the drug with to make patients lives better…”
In 2018, the average cost of developing a new drug and bringing it to market topped $2.1 billion — up $362 million from 2017 according to a Deloitte survey. One of the challenges pharmaceutical companies face is attrition and non-adherence during patient trials. Traditional methods, focused on call centers, complex documentation and feedback limitations, lack the ability to collect enough real-world evidence to get the full patient experience picture.
In this episode, Justin Mardjuki and Greg Kefer talk about the challenges the industry faces and how chatbots can be a viable option to improve the research process, during both trial and in-market phases across large patient populations.
About the Digital Conversations Podcast Series
Conversational technology and patient engagement are two technology trends sweeping through the three trillion dollar healthcare industry. In these short, interactive discussions, industry experts talk about how and where innovation is impacting the customer experience at hospitals, pharmaceutical companies, and the vast array of related services in the industry.